Cymbalta
Product Images NDC 43353-303

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Cymbalta (NDC 43353-303). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 30mg (43353 303)

Label for Duloxetine HCl (Cymbalta) DR 30 mg capsules, containing 3060 capsules. The product is manufactured by Eli Lilly and Company, Indianapolis, IN, and repackaged by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN. Storage instructions and prescription information are also present.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structural Formula (Cymbalta 01)

Chemical structure of duloxetine hydrochloride, the active ingredient in Cymbalta. The structure depicts the molecular arrangement including a thiophene ring, a naphthalene moiety, and an amine group complexed as hydrochloride salt.*

FDA Label Image

Figure 1 (Cymbalta 02)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Cymbalta (CYM) at different dosages and a placebo group. The x-axis represents percent improvement in pain from baseline (0 to 100), and the y-axis represents the percentage of patients improved (0 to 100). Four lines correspond to CYM 60 mg BID, CYM 60 mg QD, CYM 20 mg QD, and placebo, illustrating comparative treatment effects.*

FDA Label Image

Figure 2 (Cymbalta 03)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares three groups: CYM 60mg BID, CYM 60mg QD, and placebo, illustrating the efficacy of Cymbalta 60mg taken twice daily and once daily against placebo in pain improvement.*

FDA Label Image

Figure 3 (Cymbalta 13)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Cymbalta 60 mg taken twice daily, Cymbalta 60 mg taken once daily, and placebo, with patients on twice daily dosing showing higher improvement percentages across the range.*

FDA Label Image

Figure 4 (Cymbalta 14)

A line graph showing the percentage of patients improved plotted against percent improvement in pain from baseline. The graph compares four groups: Cymbalta (Cym) 120 mg once daily, 60 mg once daily, 20 mg once daily, and placebo, illustrating varying levels of pain improvement among these groups.*

FDA Label Image

Figure 5 (Cymbalta 15)

A line graph depicting the percentage of patients improved against the percent improvement in pain from baseline (BOCF). It compares two groups: Placebo and CYM60/120 mg once daily, with the CYM60/120 mg group showing a higher percentage of patients improved across most levels of pain improvement.*

FDA Label Image

Figure 6 (Cymbalta 16)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for a placebo group and a 60 mg once daily dose of Cymbalta. The graph shows higher improvement percentages for the Cymbalta group across most pain improvement thresholds.*

FDA Label Image

Figure 7 (Cymbalta 17)

A line chart comparing the percentage of patients improved versus percent improvement in pain from baseline for Cymbalta (CYM60/120 mg once daily) and placebo groups. The x-axis represents percent improvement in pain, while the y-axis shows the percentage of patients improved. Two lines illustrate that the Cymbalta group consistently shows higher patient improvement rates compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.